Histological confirmation of melanoma will be required by previous biopsy or cytology.
Histological confirmation of clear cell renal cancer
Histological Diagnosis
Histological confirmation of adenocarcinoma of the prostate within 6 months of study enrollment
Histological confirmation of follicular lymphoma grades I, II diagnosed within 12 months (365 days) prior to registration; NOTE: the day of biopsy should be used as day 1 of diagnosis for this calculation
At least one volumetrically measurable and >= 1 cc NF2-related VS (histological confirmation not required)
Histological confirmation of ER negative breast carcinoma (defined as less than 10%), stage I, II, or III
Patients with a histological diagnosis of lymphomas and/or leukemias
Confirmation of diagnosis
Evidence of active disease (histological confirmation of reactivation or progression is not required)
Have histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site which has failed prior therapy.
Histological confirmation of mycosis fungoides as confirmed by the Mayo Clinic Arizona Dermatopathology Department
Histological confirmation of stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c that is not suitable for surgical resection
Histological confirmation of breast cancer
Have histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site.
Histological confirmation of malignancy (primary tumor)
Histological confirmation of malignant carcinoma/sarcoma (any site) with metastasis to lung; histologic confirmation of the lung metastasis is not required providing there has been pathologic confirmation of malignancy
Histological confirmation of cholangiocarcinoma
Has histological confirmation of breast carcinoma.
Have histologically or cytologically documented HCC (documentation of original biopsy for diagnosis is acceptable if tumor tissue is unavailable) or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required; for subjects without cirrhosis histological confirmation is mandatory
Histological confirmation of GIST
Patients must have histological confirmation of breast carcinoma
Have histological confirmation of HER2 positive breast cancer
Histologic confirmation of malignancy
Patients must have histological confirmation of metastatic urothelial carcinoma; patients must have sufficient tumor tissues for future MTAP testing and research; histological variants such as glandular, squamous, sarcomatoid, micropapillary, plasmacytoid, and small cell changes will not be allowed for this trial unless these tumors are MTAP-deficient
Histologic confirmation is not required for this if the patient has neurofibromatosis type 1 (NF-1) with magnetic resonance imaging (MRI) findings consistent with optic pathway glioma or juvenile pilocytic astrocytoma (JPA); any other tumors will need histological confirmation, either at the time of diagnosis or at the time of recurrence; the histological diagnosis includes World Health Organization (WHO) grade I JPA
Histological documentation of mCRC
Histological confirmation of pheochromocytoma (PH)/paraganglioma (PG)
Patients must have histological confirmation of metastatic cancer with at least one metastatic or primary lesion in the liver, lung, or adrenal gland
Histological confirmation of SCLC.
Histological confirmation of relapsed/refractory CD20 positive diffuse large B-cell lymphoma; network sites must submit slides to Roswell Park for central review and confirmation
Confirmation of diagnosis
Histological diagnostic material available for review.
All patients must have histological proof of malignant cancer, which is metastatic; histological proof may be obtained from the primary tumor or another metastatic site; however, cytology alone is not an acceptable method of diagnosis
Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinoma, fibrolamellar carcinoma and hepatoblastoma
Confirmation of diagnosis:
Patients with histological confirmation of locally advanced or metastatic NSCLC
Patients must have histological confirmation of a cutaneous T-cell lymphoma (CTCL) of any histology; confirmation of histological diagnosis must be completed prior to enrollment by the lead site (Northwestern)\r\n* Patients will be stratified by mycosis fungoides (MF) and Sezary syndrome (SS) (report diagnostic or consistent with MF/SS), stage IA-IVB according to TNM blood (TNMB) classification versus other CTCL histologies
Histological confirmation of relapsed or refractory AML after prior anti-leukemic therapy by WHO Classification
Histological confirmation of adenocarcinoma of the breast
Patients have histological confirmation of invasive breast carcinoma
other histological type of lymphoma
Histological confirmation of breast carcinoma
Histological confirmation of glioblastoma
histological confirmation of transformation, or
Histological confirmation of thymoma
Histological confirmation of CTCL; a documented verifiable biopsy report is required
Patients must have histological confirmation of a brain tumor at diagnosis or relapse for all tumors
Histological or cytologic diagnosis of squamous cell cancer
Patients have histological confirmation of breast carcinoma
Patients with histological or cytologically documented hepatocellular carcinoma (HCC) (documentation of original biopsy for diagnosis is acceptable if tumor tissue is unavailable) or clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic subjects is required; for subjects without cirrhosis histological confirmation is mandatory
Subjects must have a histological diagnosis of cancer
Histological confirmation of malignancy (primary or metastatic tumor)
Confirmation of:
Histological confirmed diagnosis of relapsed intracranial GB
Subjects with histological confirmation of RCC
Histological confirmation of malignancy (primary or metastatic tumor)
Histological confirmation of breast carcinoma; pathologic evidence of dermal lymphatic invasion should be noted but not required
Prior surgery for a low grade tumor is allowed, provided histological confirmation of anaplastic tumor is present at the time of progression
(2. continued) Patients with prior therapy that included interstitial brachytherapy, Gliadel wafers or stereotactic radiosurgical procedures must have confirmation of true progressive disease rather than radiation necrosis. Such confirmation may be using advanced imaging studies (e.g. PET scans, diffusion-perfusion MRI, SPECT etc) or if available, surgical sampling and histological confirmation (surgery is not required).
Histological diagnosis of GIST.
Histologic confirmation not required if other diagnostic criteria are met;
Histological or cytologic confirmation of unresectable or metastatic cholangiocarcinoma (intrahepatic, hilar, extrahepatic bile duct)
Histological diagnosis of cancer
No histological confirmation of breast cancer
Histological diagnosis of high-grade osteosarcoma
All patients with a histological diagnosis of cancer
Histological confirmation of breast cancer
Histological diagnosis of NET
Histological confirmation of prostate cancer
Histological confirmation of prostate cancer
Histological confirmation of prostate cancer
T1 and T2 (< 3.5 cm), N0, M0, confirmed by clinical, cytological or histological examination
Histological or cytological proof of prostate cancer
Histological or cytological evidence of confirmed metastatic pancreatic or advanced bladder cancer
Histological or cytological diagnosis of metastatic cancer or locally advanced cancer that is not amenable to local therapy
Subject must have histological or cytological evidence of a solid malignancy
Histological or cytological proof of prostate cancer
For dose escalation for all combinations: The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced or metastatic.
Patients must have histological or cytological evidence of a solid neoplasm
Histological or cytological diagnosis of adenocarcinoma of the prostate
Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
Histological or cytological confirmation diagnosis of NSCLC.
Patients must have advanced or metastatic NSCLC with histological or cytological confirmation. Patients with known EGFR-activating mutations or ALK rearrangements are excluded.
Patients must have metastatic prostate cancer with histological or cytological confirmation.
Must have histological or cytological evidence of a diagnosis of cancer that is not amenable to curative therapy.
Histological or cytological diagnosis of solid cancer or lymphoma that is considered incurable and without therapies with established benefit. Biopsy is not necessary for subjects with known prior diagnosis and clinical or radiographic evidence of recurrence.
Patients must have documented histological or cytological evidence of tumor(s) of the prostate.
Histological, molecular or cytological confirmation of: Part A:
Advanced stage solid tumors as documented by histological or cytological evidence, with no available approved therapies known to cure metastatic disease or extend survival, and who have received all standard therapy.
Histological or cytological proof of prostate cancer
Histological or cytological evidence/confirmation of urothelial cancer.
Histological or cytological confirmation diagnosis of stage 4 NSCLC
Parts B of the study will include patients with histological or cytological confirmation diagnosis of locally advanced or metastatic Stage IV NSCLC.
Part C of the study will include patients with histological or cytological confirmation diagnosis of locally advanced or metastatic Stage IV 1st-line NSCLC (for which the patient has not received therapy).
The participant must have histological or cytological evidence of a diagnosis of solid tumor, excluding lymphomas and melanoma, but including central nervous system (CNS) tumors, that is relapsed or refractory, not be amenable to curative treatment.
Participant must have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic.
Histological or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Subjects must have histological or cytological documentation of locally advanced, recurrent, or metastatic renal cell carcinoma
Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (Stage IV) and not amenable to resection with curative intent.
Histological or cytological proof of prostate adenocarcinoma (Note: small-cell carcinoma of the prostate is not permitted)
The participant must have histological or cytological evidence of cancer.
Histological or cytological confirmation of colorectal cancer (CRC) with available tissue, currently stage IV
Diagnosis of uveal melanoma with histological or cytological confirmed metastatic disease. Disease must be treatment naive or have progressed (radiologically or clinically) on most recent therapy.
Histological or cytological evidence of metastatic prostate cancer with progression defined in PCWG3; Scher HI 2015 and intolerance of standard chemotherapy
Histological or cytological evidence of solid malignancy.
Histological/cytological diagnosis of primary HCC
Histological or cytological documentation of adenocarcinoma of the colon or rectum
Histological or cytological diagnosis of metastatic CRC excluding known microsatellite instable sub-types, metastatic SCCHN or metastatic NSCLC that have progressed or have become intolerant to standard therapy, and whose disease may allow management with other available therapies
Histological or cytological diagnosis of metastatic squamous or non-squamous NSCLC.
Patient has histological and/or cytological confirmed ER+ and/or PgR+ aBC
Patients must have histological or cytological confirmed melanoma that is metastatic or that is unresectable stage III and clearly progressive
Subjects must have documented histological or cytological evidence of adenocarcinoma of the prostate.
Histological or cytological diagnosis of HCC.
Histological or cytological diagnosis of ductal adenocarcinoma of the pancreas.
Documentation of histological or cytological confirmation of estrogen receptor positive (ER+) and HER2 negative adenocarcinoma of the breast must be available.
For Dose Escalation (Part A): The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced or metastatic.
Patients must have histological, pathological and/or cytological confirmation of prostate cancer.
Patients must have histological, pathological and/or cytological confirmation of prostate cancer
Histological or cytological confirmation of ER+ and/or PR+ breast cancer
Histological or cytological evidence of prostate adenocarcinoma.
Histological or cytological confirmation of epidermoid anal carcinoma (includes squamous, basaloid and cloacogenic lesions) from the primary tumor or a newly diagnosed recurrent/metastatic lesion
Patients with histological or cytological proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced, inoperable and/or metastatic disease
Histological or cytological confirmed small cell lung cancer (SCLC)
Female subjects ? 21 years of age with histological or cytological diagnosis of breast carcinoma.
Histological or cytological diagnosis of metastatic cancer or locally advanced cancer that is not amenable to local therapy
Have histological or cytological evidence of colorectal adenocarcinoma with confirmation of metastatic disease either by pathologic or radiologic findings.
Histological or cytological documentation of adenocarcinoma of the colon or rectum
Patients must have documented histological or cytological evidence of adenocarcinoma of the prostate.
Histological or cytological evidence of NSCLC
Histological/cytological confirmation of biliary cancer
Histological or cytological documentation of adenocarcinoma of the colon or rectum;
Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
Subjects must have a cytological or histological confirmed diagnosis of adenocarcinoma of the lung.
Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer (NSCLC).
Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
Histological or cytological proof of colorectal or pancreatic adenocarcinoma
For Dose Escalation (Part A): The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced and/or metastatic
For Dose Expansion (Parts B, C, D, E, F and G): The participant must have histological or cytological evidence of one of the following cancers:
Histological or cytological documentation of adenocarcinoma of the colon or rectum
Histological or cytological diagnosis of adenocarcinoma of the prostate
Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin
Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin in conjunction with either:
Histological or cytological evidence of malignancy.
Patients must have histological or cytological confirmed melanoma that is metastatic or unresectable stage IIIc and clearly progressive.
Has recurrent or metastatic carcinoma of the colon or rectum with documented histological or cytological confirmation;
For Part A, the subject has histological or cytological evidence of a solid tumor; for Part B, the subject has histological or cytological evidence of 1 of the following solid tumor types: melanoma, renal cell carcinoma, or ovarian cancer
Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or metastatic cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy
Histological or cytological confirmed metastatic colorectal cancer
Age = or > 18 years Histological or cytological diagnosis of undifferentiated or poorly differentiated nasopharyngeal carcinoma that is locally advanced or metastatic.
Part A: Histological or cytological confirmation of a solid tumor and disease progression. Part B: Histological or cytological confirmation of ER positive, HER2 negative breast cancer and disease progression or any other solid tumor with a PIK3CA gene mutation. Part C: Histological or cytological confirmation of ER positive, HER2 negative postmenopausal breast cancer with locally advanced or metastatic disease that is eligible for fulvestrant treatment. Part D: Histological or cytological confirmation of ER positive, HER2 negative postmenopausal breast cancer with locally advanced or metastatic disease that is eligible for fulvestrant treatment. Patients must also present with a tumor related mutation of the PIK3CA gene.
Participants must have histological or cytological confirmed melanoma that is metastatic or unresectable and clearly progressive
Inclusion Criteria for group A and B:\n\n          -  Weight loss < 10% in the last three months.\n\n          -  WHO-performance status ? 2\n\n          -  Medical inoperable patients or patients refusing surgery.\n\n          -  Chemotherapy is allowed in neoadjuvant and adjuvant setting, with exclusion of the\n             period 4 weeks pre-SBRT and 6 weeks post-SBRT.\n\n          -  Before patient registration, written informed consent must be given according to\n             ICH/GCP, national and local regulations.\n\n        Risk group A specification:\n\n          -  NSCLC (Cytological or histological proven) patients with peripheral tumors >5 cm with\n             tumor staging cT2bN0M0 or cT3N0M0 (chest wall infiltration is no exclusion criteria,\n             as long as the tumor diameter is > 5 cm).\n\n          -  Single peripheral lung metastasis in inoperable patients with a diameter of > 5 cm. In\n             case of first presentation of metastatic disease, cytological or histological proof is\n             obligated.\n\n          -  In patients without cytological or histological confirmation of NSCLC, a growing\n             FDG-PET positive lesion (SUV >5) is accepted if a contra-indication for invasive\n             diagnostic examination (or refusal) is present.\n\n        Risk group B specification:\n\n          -  Patients with ? 2 simultaneous peripheral lung metastases ? 5 cm of any origin at any\n             location in the lung.\n\n          -  In case of first presentation of metastatic disease, cytological or histological proof\n             is obligated. This is not necessary in case of a history of an already proven\n             disseminated disease.\n\n          -  Patients having ? 2 peripheral lung metastases without unacceptable dose overlap.\n\n        Exclusion Criteria:\n\n          -  Patients with central tumors\n\n          -  Pancoast tumors\n\n          -  Prior radiotherapy treatment to the thorax\n\n          -  Patients receiving any systemic treatment during SBRT\n\n          -  Pregnant patients\n\n          -  Patients previously treated with adriamycin agents in case of heart involvement within\n             the treatment field.
No histological or cytological diagnosis of NSCLC; this includes failure to make an intraoperative diagnosis of malignancy at the time of ENB
Cytological or histological confirmed diagnosis of hepatocellular carcinoma that is locally advanced or metastatic and is not amenable to treatment with surgery or to orthotopic liver transplant (Phase II)
Patients must have a cytological or histological diagnosis of adenocarcinoma arising in the pancreas; adenosquamous cancers will be acceptable
Part A: Have histological or cytological evidence of cancer (solid tumor, lymphoma, or multiple myeloma) that is advanced and/or metastatic and an appropriate candidate for experimental therapy
Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy.
Histological or cytological proof of prostate adenocarcinoma
Histological or cytological confirmed ER and/or PR positivity
Histological or cytological confirmation of NSCLC
Documentation of histological or cytological confirmation of estrogen receptor positive (ER+) and HER2 negative adenocarcinoma of the breast must be available.
Histological/cytological confirmation of oral cavity dysplasia or prior history of OSCC
Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic
Histological or cytological confirmation of an ER+ advanced metastatic breast cancer tumour that is eligible for treatment with fulvestrant
Histological or cytological diagnosis of prostate cancer
Histological or cytological documentation of an advanced solid tumor
No inflammatory breast cancer
Participant with inflammatory breast cancer.
Inflammatory breast cancer
Diagnosis of inflammatory breast cancer
FOR ALL PHASES (Ib AND II): Inflammatory breast cancer
Inflammatory breast cancer
Diagnosis of inflammatory breast carcinoma
Inflammatory (T4d) breast cancer
Documentation of inflammatory breast cancer
Inflammatory breast cancer or patients with rapidly progressing metastatic breast cancer
Diagnosis of inflammatory breast cancer
Have no inflammatory breast cancers
Patients with bilateral or inflammatory breast cancer
Inflammatory breast cancer
Inflammatory breast cancer
Patients with inflammatory breast carcinoma
Patients with inflammatory breast cancer
Bilateral or inflammatory breast cancer
Inflammatory breast cancer
Inflammatory breast cancer or tumor with deep adherence or cutaneous invasion
Diagnosis of inflammatory breast cancer
Patients must have the clinical diagnosis of inflammatory breast cancer
Patients with inflammatory breast cancer
Subject has inflammatory breast cancer
Inflammatory breast cancer
Patients must not have inflammatory breast cancer and must not have metastatic disease
Active inflammatory breast cancer
Patient with inflammatory breast cancer at screening
Subject has inflammatory breast cancer
Inflammatory breast cancer or tumor with deep adherence or cutaneous invasion;
Subjects with Inflammatory breast cancer.
Inflammatory breast cancer
Patient with inflammatory breast cancer at screening .
Patients who currently have inflammatory breast cancer at screening.
Have inflammatory breast cancer
Inflammatory/inoperable breast cancer.
Patients must not have inflammatory breast cancer (T4d) and must not have metastatic breast cancer (stage IV disease)
Male and female participants with locally advanced, inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast cancer. Participants with inflammatory breast cancer must be able to have a core needle biopsy
Evidence of inflammatory breast cancer
Inflammatory breast cancer.
Inflammatory breast cancer
Patient with inflammatory breast cancer
Inflammatory or metaplastic breast cancer
Subjects with inflammatory breast cancer
Subjects with a diagnosis of non-inflammatory breast cancer or carcinoma in situ
Subjects with Inflammatory breast cancer.
Patients with inflammatory breast cancer are eligible for the escalation phase of the mastectomy cohort
Inflammatory breast cancer patients are ineligible, except in the escalation phase of the mastectomy cohort
Inflammatory breast malignancy
Participants with inflammatory breast cancer or multi-centric disease
Participants with locally advanced breast cancer such as inflammatory breast cancer or cancer grossly involving skin
Inflammatory breast cancer
Patients with stage T1 or greater (T1-T4), nodal involvement (N0-N3), without metastasis (M0) invasive breast cancer, including patients with inflammatory breast cancer
Any patient with confirmed metastatic disease. Patients with inflammatory breast cancer.
